Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study)

Trial Profile

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RE-LY
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2017 Outcomes of a novel biomarker-based risk score (development, validation and calibration) estimating the risk of death in two large cohorts of patients (ARISTOTLE and RE-LY) with atrial fibrillation receiving oral anticoagulation, published in the European Heart Journal.
    • 20 Sep 2017 Results (n=3623) evaluating risk scores for major bleeding in patients with atrial fibrillation, published in the Stroke.
    • 30 Aug 2017 Results (n=23159) of a study developing and validating new biomarker based risk score for stroke and bleeding using patient data from ARISTOTLE and RE-LY trials presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top